The Longevity Industry
The longevity industry aims to challenge the notion that age-related diseases are inevitable consequences of growing older. By targeting specific biological processes, researchers seek to slow down or reverse these conditions. Key areas of research include developing therapies, exploring regenerative approaches, and studying the impact of diet and lifestyle. This industry encompasses companies dedicated to developing new technologies and treatments for aging and longevity. Global funding for longevity research reached $1.3 billion in 2018. Notable players include Unity Biotechnology, BioMarin, Insilico Medicine, Juvenescence, and Celularity. Promising longevity drugs include senolytics, aging pathway targets, regenerative agents, and caloric restriction mimetics. Deloitte’s article provides valuable insights.
